Alzheimer's Drugs Lecanemab and Donanemab Spark Controversy Despite Slowing Disease Progression

Two new drugs, lecanemab查看药品详情 (Leqembi) and donanemab查看药品详情 (Kisunla), representing the first treatments capable of slowing the progression of Alzheimer's disease (搜索)搜索该疾病, have ignited a significant medical controversy. Developed by Biogen查看公司主页/Eisai查看公司主页 and Eli Lilly查看公司主页, respectively, these drugs have divided the medical community, with some hailing them as a breakthrough and others viewing them as another disappointment in a field plagued by failures.

While the United States has approved both lecanemab查看药品详情 and donanemab查看药品详情, the European Union rejected lecanemab, casting doubt on donanemab's prospects for approval there. The UK has taken a middle ground, approving lecanemab but not making it available through the National Health Service.

Limited Efficacy and Significant Risks

Clinical trial data indicates that both drugs can reduce cognitive decline in patients with early-stage Alzheimer's by about 30%. However, critics argue that this benefit is marginal, especially when weighed against the potential risks, including brain swelling and bleeding, which have been fatal in rare cases. Rob Howard, a professor of old age psychiatry at University College London, stated, "The benefits are so tiny as to be practically invisible in an individual patient."

Cost and Accessibility Concerns

A major point of contention is the exorbitant cost of these treatments. A 2023 study estimated that treating all eligible patients in the EU with lecanemab查看药品详情 would cost 133 billion euros ($148 billion). This raises concerns about equitable access, with some fearing that only wealthy individuals will be able to afford the drugs, potentially creating disparities in treatment availability.

The Amyloid Plaque Hypothesis

The development of lecanemab查看药品详情 and donanemab查看药品详情 is rooted in the amyloid plaque hypothesis, which posits that amyloid plaques (搜索)搜索该靶点 in the brain are a primary driver of Alzheimer's disease (搜索)搜索该疾病. This theory gained prominence following a 1992 article by British biologist John Hardy. While many previous drugs targeting amyloid plaques failed, lecanemab and donanemab have shown some success in slowing cognitive decline, reigniting the debate about the role of amyloid in Alzheimer's.

Differing Perspectives and Future Directions

Despite the controversies, many neurologists advocate for the use of lecanemab查看药品详情 and donanemab查看药品详情, believing they can offer patients valuable additional months of autonomy. They also suggest that earlier intervention, made possible by advancements in diagnostic techniques, could enhance the drugs' effectiveness.

However, some experts caution against relying solely on amyloid-targeting therapies. A doctor working for Eli Lilly查看公司主页, who wished to remain anonymous, criticized Biogen查看公司主页 for overstating the benefits of its previous Alzheimer's treatment, Aduhelm查看药品详情, which was later withdrawn after a controversial approval. This expert emphasized the need to explore other mechanisms underlying Alzheimer's disease (搜索)搜索该疾病, suggesting that single-target treatments may have limited impact. As a group of experts wrote in the Journal of Prevention of Alzheimer's Disease last month, it is unlikely that "single-target treatments will achieve substantially larger effects" than lecanemab查看药品详情 and donanemab查看药品详情, but the new drugs are a "critical step" in Alzheimer's treatment.